Integra LifeSciences Holdings Corporation
NASDAQ:IARTMedical - Devices
+$0.81 today
- Market cap
- $1.08B
- Beta
- 1.25
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$6.44
Volume 0.58M
Average 0.96M
IART Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Integra LifeSciences Holdings CorporationNASDAQ: IART
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows in line with its trailing trend
Q1 FY2026 revenue of $391.92M rose 2.4% year over year, ahead of the +1.2% change in trailing-twelve-month revenue. Sequentially, it fell 9.9% from the prior quarter. Over 3 fiscal years it compounded at +1.6% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $1.64B (+0.5%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $391.92M-9.9% QoQ
- Last fiscal yearDec 2025
- $1.64B+1.5% YoY
- LTMMar 2026
- $1.64B+1.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.4% | +0.5% | -2.0 pp |
| 1 year | +1.5% | +0.5% | -1.0 pp |
| 3-year CAGR | +1.6% | +2.0% | +0.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 1.64B USD
- Year-over-year change
- +1.5%
- 4-year CAGR
- +1.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.64B | +1.5% |
| FY2024 | 2024-12-31 | 1.61B | +4.5% |
| FY2023 | 2023-12-31 | 1.54B | -1.0% |
| FY2022 | 2022-12-31 | 1.56B | +1.0% |
| FY2021 | 2021-12-31 | 1.54B | — |
Revenue vs competitors
How IART compares with its peers on the latest reported figures
- IART's LTM Mar 2026 revenue of $1.64B is the 4th highest of the 11 companies compared; the peer median is $806.23M.
- Its year-over-year change of +1.2% is the 10th highest of 11, against a peer median of +7.3%.
- Over three fiscal years its annual growth of +1.6% compares with a peer median of +19.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $25.84B | +8.5% | +10.8% | |
| FY2025 | $6.16B | +6.1% | +5.7% | |
| LTM Jun 2026 | $3.14B | +19.7% | +42.2% | |
| LTM Mar 2026 | $1.64B | +1.2% | +1.6% | |
| LTM Mar 2026 | $1.37B | +4.4% | +9.5% | |
| LTM Mar 2026 | $825.37M | +2.6% | +21.3% | |
| LTM Mar 2026 | $787.08M | +22.5% | +29.6% | |
| LTM Mar 2026 | $458.69M | +17.6% | +12.0% | |
| LTM Sep 2026 | $266.93M | +24.3% | +17.6% | |
| LTM Mar 2026 | $121.91M | -0.3% | +32.2% | |
| LTM Jun 2026 | $79.91M | +6.1% | +24.7% | |
| Peer median (excluding IART) | $806.23M | +7.3% | +19.4% | |
Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B |
| Cost of Revenue | 597.81M | 587.36M | 656.84M | 728.47M | 790.01M |
| Gross Profit | 944.64M | 970.31M | 884.74M | 882.06M | 845.23M |
| Gross Margin | 61.2% | 62.3% | 57.4% | 54.8% | 51.7% |
| Research & Development | 93.05M | 101.19M | 104.19M | 115.38M | 98.97M |
| Selling, General & Admin | 637.45M | 616.32M | 656.64M | 716.98M | 699.7M |
| Operating Expenses | 747.41M | 731.39M | 773.21M | 853.65M | 776.92M |
| Depreciation & Amortization | 123.67M | 121.12M | 123.51M | 140.5M | 151.05M |
| EBITDA | 366.33M | 384.6M | 255.96M | 193.29M | (326.2M) |
| EBITDA Margin | 23.7% | 24.7% | 16.6% | 12.0% | -19.9% |
| Operating Income | 197.23M | 238.92M | 111.53M | 28.41M | 68.32M |
| Operating Margin | 12.8% | 15.3% | 7.2% | 1.8% | 4.2% |
| Interest Income | 6.74M | 11.92M | 17.2M | 20.04M | 18.47M |
| Interest Expense | 50.4M | 49.59M | 51.38M | 70.63M | 86.26M |
| Other Income / Expenses | 17.45M | (25.03M) | (30.46M) | (46.65M) | (631.82M) |
| Income Before Tax | 214.68M | 213.89M | 81.07M | (18.24M) | (563.5M) |
| Pre-Tax Margin | 13.9% | 13.7% | 5.3% | -1.1% | -34.5% |
| Income Tax Expense | 45.6M | 33.34M | 13.33M | (11.29M) | (47.03M) |
| Net Income | 169.08M | 180.55M | 67.74M | (6.94M) | (516.47M) |
| Net Margin | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
| EPS (Basic) | 2.00 | 2.18 | 0.87 | (0.09) | (6.73) |
| EPS (Diluted) | 1.98 | 2.16 | 0.84 | (0.09) | (6.73) |
| Weighted Avg Shares | 84.7M | 83M | 78.17M | 77.01M | 76.75M |
| Weighted Avg Shares (Diluted) | 85.49M | 83.52M | 80.34M | 77.01M | 76.75M |
Integra LifeSciences Holdings Corporation
NASDAQ:IART
Intrinsic Alpha fair value
Locked
Current Price
$13.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.